Clemizole HCl + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lennox Gastaut Syndrome
Conditions
Lennox Gastaut Syndrome
Trial Timeline
Apr 9, 2025 → Nov 1, 2029
NCT ID
NCT05066217About Clemizole HCl + Placebo
Clemizole HCl + Placebo is a phase 3 stage product being developed by Harmony Biosciences for Lennox Gastaut Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05066217. Target conditions include Lennox Gastaut Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05066217 | Phase 3 | Recruiting |
| NCT04462770 | Phase 3 | Recruiting |
Competing Products
11 competing products in Lennox Gastaut Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + Perampanel | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Pre-clinical | 23 |
| Rufinamide (E2080) + Placebo | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Pre-clinical | 23 |
| Rufinamide | Eisai | Phase 3 | 77 |
| Rufinamide + Any other approved Antiepileptic Drug | Eisai | Phase 3 | 77 |
| ZX008 0.2 or 0.8 mg/kg/day + Matching Placebo | UCB | Phase 3 | 74 |
| Clobazam | Lundbeck | Phase 3 | 74 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Pre-clinical | 20 |
| Cannabidiol | Jazz Pharmaceuticals | Approved | 82 |
| GWP42003-P | Jazz Pharmaceuticals | Approved | 82 |